SYNAGIS 50MG/0.5ML(PALIVIZUMAB)

About SYNAGIS 50MG/0.5ML(PALIVIZUMAB)

Synagis 50mg Injection contains the active substance Palivizumab, a monoclonal antibody used primarily to prevent severe respiratory syncytial virus (RSV)-related lower respiratory tract infections in high-risk children. 

Synagis 50mg Injection is prescribed to infants and young children at high risk for severe RSV infection, including those born prematurely (35 weeks gestational age), those with bronchopulmonary dysplasia (BPD), and children with hemodynamically significant congenital heart disease (CHD). It works by inhibiting the RSV F protein, preventing the virus from entering and infecting healthy cells. 

Before starting treatment with Synagis 50mg Injection, inform your doctor if your child has any history of allergies or bleeding disorders, as well as any other medications they are currently taking. While Synagis 50mg Injection is generally well-tolerated, regular monitoring is recommended, particularly for any signs of hypersensitivity reactions or coagulation disorders.